歯周ポルフィロモナス・ジンジバリスワクチン:世界の市場機会分析・予測

◆英語タイトル:MarketVIEW: Periodontal P.gingivalis vaccines - Global vaccine commercial opportunity assessment
◆商品コード:VAZ2006008
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2019年9月
◆ページ数:n/a
◆レポート言語:英語
◆レポート形式:Executive presentation (~100 slides.pdf) + 1 x MS-Excel forecast model (.xls)
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Region PriceUSD7,995 ⇒換算¥831,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
VacZine Analytics社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Periodontal disease or ‘gum disease’ is a hugely prevalent inflammatory condition in adults affecting around two-thirds of the world population (mild/moderate and severe disease). The disease has become a global health concern and exerts substantial economic burden on healthcare systems due to the cost of mechanical surgical, dental treatment.
The bacterium Porphyromonas gingivalis (P. gingivalis) has been identified as a ‘keystone’ dysbiotic pathogen in periodontitis which causes impaired immunity through its interaction with the host complement system. The bacterium has a high prevalence in periodontitis patients and an association with alveolar bone loss. Research studies have demonstrated that specific blocking of P. gingivalis can reverse dysbiotic effects and protect against periodontal disease indictors, thereby implicating this mechanism as a potential therapy. In addition to its involvement in periodontal diseases, P. gingivalis also has a demonstrated association with many other chronic diseases such as cardiovascular, kidney, metabolic, respiratory disorders, cancer and has even more recently been implicated in Alzheimer’s disease. Evidence for its association and potential involvement in the pathogenesis of these additional chronic conditions is further strengthening a hypothesis for its selective targeting with a therapeutic small molecule or vaccine.

This MarketVIEW contains a comprehensive MS Excel-based model + Executive presentation that forecasts the potential commercial value of P. gingivalis vaccines across Western economies until 2040. The model contains value ($ m) and volume (million doses) predictions for an example vaccine-targeted segment along with timeframe, pricing and penetration estimates. The product also includes an in-depth review of periodontitis disease, epidemiology, treatments/guidelines and most recent developments in R&D (academic and commercial). It is an ideal �first pass� look at this intriguing vaccine opportunity. THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL

To order please contact your region account manager, buy “on-line” or order direct at: orders@vaczine-analytics.com

【レポートの目次】

PRODUCT CONTENTS:
Published September 2019 (CAT No: VAMV086)
****This product is a summary presentation (.pdf), a forecast model (.xls)
Contents – Summary presentation (.pdf)1
Contents
Author’s notes
Executive summary
[SECTION 1] P. gingivalis vaccines: key commercial model outputs
[SECTION 2] Periodontal diseases: disease background and treatments
[SECTION 3] Periodontal diseases epidemiology
[SECTION 4] Periodontitis: P. gingivalis and the pathogenesis of disease
[SECTION 5] P. gingivalis and the association with chronic diseases
[SECTION 6] P. gingivalis vaccines: research, development and current progress
[SECTION 7] P. gingivalis vaccines: modelling commercial potential
Bibliography
About VacZine Analytics
Disclaimer
PAGES: ~100 slides fully referenced/sourced. Available in .pdf form
Contents – Vaccine model (MS Excel-based)
Worksheets = >20 interconnected sheets



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[歯周ポルフィロモナス・ジンジバリスワクチン:世界の市場機会分析・予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆